{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:20:23Z","timestamp":1791822023428,"version":"4.3.4"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006301","name":"Center for International Business Education and Research, University of Illinois at Urbana-Champaign","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021-122116OB-100"],"award-info":[{"award-number":["PID2021-122116OB-100"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.tips.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T16:08:30Z","timestamp":1745856510000},"page":"551-566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD"],"prefix":"10.1016","volume":"46","author":[{"given":"Xavier","family":"Palomer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue-Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Escalona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Wahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7138-8207","authenticated-orcid":false,"given":"Manuel","family":"V\u00e1zquez-Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.03.008_bb0005","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2025.03.008_bb0010","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.03.008_bb0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2025.03.008_bb0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/liv.15766","article-title":"Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score","volume":"44","author":"Marti-Aguado","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.tips.2025.03.008_bb0025","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2025.03.008_bb0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcmgh.2023.09.008","article-title":"The origin and fate of liver myofibroblasts","volume":"17","author":"Kim","year":"2024","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2025.03.008_bb0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.gastro.2020.05.046","article-title":"Why do so many nonalcoholic steatohepatitis trials fail?","volume":"165","author":"Ratziu","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2025.03.008_bb0040","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.03.008_bb0045","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2025.03.008_bb0050","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Phase 2a Trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2025.03.008_bb0055","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1074\/jbc.M114.598011","article-title":"Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion","volume":"290","author":"Ramezani-Moghadam","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2025.03.008_bb0060","doi-asserted-by":"crossref","first-page":"12279","DOI":"10.1074\/jbc.REV120.011356","article-title":"From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases","volume":"295","author":"Zhao","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2025.03.008_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100676","article-title":"Targeting acetyl-CoA carboxylases for the treatment of MASLD","volume":"65","author":"Mateo-Marin","year":"2024","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.tips.2025.03.008_bb0070","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.celrep.2017.03.011","article-title":"Liver-specific activation of AMPK prevents steatosis on a high-fructose diet","volume":"18","author":"Woods","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2025.03.008_bb0075","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.03.008_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4062\/biomolther.2024.188","article-title":"New insights into AMPK, as a potential therapeutic target in metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis","volume":"33","author":"An","year":"2025","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.tips.2025.03.008_bb0085","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.tem.2023.08.011","article-title":"Metabolic control by AMPK in white adipose tissue","volume":"34","author":"Goransson","year":"2023","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tips.2025.03.008_bb0090","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ebiom.2018.01.008","article-title":"AMPK re-activation suppresses hepatic steatosis but its downregulation does not promote fatty liver development","volume":"28","author":"Boudaba","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.tips.2025.03.008_bb0095","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1007\/s00018-010-0454-z","article-title":"AMP-activated protein kinase and its downstream transcriptional pathways","volume":"67","author":"Canto","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tips.2025.03.008_bb0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MOL.0b013e328328d0a4","article-title":"PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure","volume":"20","author":"Canto","year":"2009","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.tips.2025.03.008_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103230","article-title":"Alpha-ketoglutarate prevents hyperlipidemia-induced fatty liver mitochondrial dysfunction and oxidative stress by activating the AMPK-pgc-1alpha\/Nrf2 pathway","volume":"74","author":"Cheng","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.tips.2025.03.008_bb0110","doi-asserted-by":"crossref","first-page":"27628","DOI":"10.1074\/jbc.M805711200","article-title":"SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation","volume":"283","author":"Lan","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2025.03.008_bb0115","article-title":"Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis","volume":"7","author":"Lamas-Paz","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.tips.2025.03.008_bb0120","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.3390\/ijms25115822","article-title":"Pin1 exacerbates non-alcoholic fatty liver disease by enhancing its activity through binding to ACC1","volume":"25","author":"Jin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.03.008_bb0125","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s12072-023-10622-w","article-title":"The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK\/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver disease","volume":"18","author":"Wu","year":"2024","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.tips.2025.03.008_bb0130","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s10753-020-01242-9","article-title":"Role of silent information regulator 1 (SIRT1) in regulating oxidative stress and inflammation","volume":"43","author":"Singh","year":"2020","journal-title":"Inflammation"},{"key":"10.1016\/j.tips.2025.03.008_bb0135","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1452696","article-title":"PGC-1alpha, inflammation, and oxidative stress: an integrative view in metabolism","volume":"2020","author":"Rius-Perez","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.tips.2025.03.008_bb0140","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34152","article-title":"Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases","volume":"7","author":"Xiong","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.tips.2025.03.008_bb0145","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ncb1724","article-title":"p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation","volume":"10","author":"Kawauchi","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tips.2025.03.008_bb0150","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tem.2017.10.009","article-title":"AMP-activated protein kinase regulation of the NLRP3 inflammasome during aging","volume":"29","author":"Cordero","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tips.2025.03.008_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103159","article-title":"SLC7A11\u2013ROS\/alphaKG\u2013AMPK axis regulates liver inflammation through mitophagy and impairs liver fibrosis and NASH progression","volume":"72","author":"Lv","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.tips.2025.03.008_bb0160","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ajpath.2023.08.007","article-title":"The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) Pathogenesis","volume":"193","author":"Venkatesan","year":"2023","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tips.2025.03.008_bb0165","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12561","article-title":"Reduced delivery of epididymal adipocyte-derived exosomal resistin is essential for melatonin ameliorating hepatic steatosis in mice","volume":"66","author":"Rong","year":"2019","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.tips.2025.03.008_bb0170","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2025.03.008_bb0175","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1126\/science.aay0542","article-title":"An AMPK\u2013caspase-6 axis controls liver damage in nonalcoholic steatohepatitis","volume":"367","author":"Zhao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.03.008_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the treatment of NASH \u2013 two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human","volume":"11","author":"Henriksson","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.tips.2025.03.008_bb0185","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tem.2024.02.001","article-title":"Current status and future perspectives of FGF21 analogues in clinical trials","volume":"35","author":"Chui","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tips.2025.03.008_bb0190","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.32404","article-title":"FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase\u2013caspase 6 signal axis","volume":"76","author":"Song","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.tips.2025.03.008_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155772","article-title":"GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-beta1\/SMAD3 pathway","volume":"152","author":"Jurado-Aguilar","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.tips.2025.03.008_bb0200","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.clnu.2024.08.007","article-title":"FNDC4 reduces hepatocyte inflammatory cell death via AMPKalpha in metabolic dysfunction-associated steatotic liver disease","volume":"43","author":"Neira","year":"2024","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.tips.2025.03.008_bb0205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1042\/EBC20240007","article-title":"New developments in AMPK and mTORC1 cross-talk","volume":"68","author":"Smiles","year":"2024","journal-title":"Essays Biochem."},{"key":"10.1016\/j.tips.2025.03.008_bb0210","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi0759","article-title":"Found in translation \u2013 fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)","volume":"15","author":"Wang","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2025.03.008_bb0215","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022129","article-title":"Non-Smad signaling pathways of the TGF-beta family","volume":"9","author":"Zhang","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.tips.2025.03.008_bb0220","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.taap.2017.06.012","article-title":"Modulation of TGF-beta\/Smad and ERK signaling pathways mediates the anti-fibrotic effect of mirtazapine in mice","volume":"329","author":"El-Tanbouly","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tips.2025.03.008_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115663","article-title":"Promising small molecule anti-fibrotic agents: newly developed or repositioned drugs targeting myofibroblast transdifferentiation","volume":"214","author":"Ishikane","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2025.03.008_bb0230","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jcp.22824","article-title":"AMP-activated protein kinase inhibits TGF-beta-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300","volume":"227","author":"Lim","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tips.2025.03.008_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117303","article-title":"PPARbeta\/delta attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells","volume":"179","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tips.2025.03.008_bb0240","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.cmet.2020.04.011","article-title":"Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis","volume":"31","author":"Jian","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2025.03.008_bb0245","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00109-015-1313-z","article-title":"Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells","volume":"93","author":"Dong","year":"2015","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.tips.2025.03.008_bb0250","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000480","article-title":"Repurposing of the analgesic neurotropin for MASLD\/MASH treatment","volume":"8","author":"Tsuchiya","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.tips.2025.03.008_bb0255","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146243","article-title":"Myofibroblast YAP\/TAZ activation is a key step in organ fibrogenesis","volume":"7","author":"He","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2025.03.008_bb0260","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","article-title":"Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine","volume":"19","author":"Dey","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2025.03.008_bb0265","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1038\/s41598-024-55764-5","article-title":"AMPK stimulation inhibits YAP\/TAZ signaling to ameliorate hepatic fibrosis","volume":"14","author":"Shihan","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.03.008_bb0270","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13578-024-01315-4","article-title":"Knockdown of hepatic mitochondrial calcium uniporter mitigates MASH and fibrosis in mice","volume":"14","author":"Li","year":"2024","journal-title":"Cell Biosci."},{"key":"10.1016\/j.tips.2025.03.008_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2024.135480","article-title":"Vitamin D receptor attenuates carbon tetrachloride-induced liver fibrosis via downregulation of YAP","volume":"478","author":"Wang","year":"2024","journal-title":"J. Hazard. Mater."},{"key":"10.1016\/j.tips.2025.03.008_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100564","article-title":"Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice","volume":"65","author":"Nunes","year":"2024","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.tips.2025.03.008_bb0285","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.celrep.2018.12.036","article-title":"Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD","volume":"26","author":"Garcia","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2025.03.008_bb0290","doi-asserted-by":"crossref","first-page":"E730","DOI":"10.1152\/ajpendo.00225.2016","article-title":"Treatment of nonalcoholic fatty liver disease: role of AMPK","volume":"311","author":"Smith","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2025.03.008_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106578","article-title":"A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects","volume":"187","author":"Aguilar-Recarte","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2025.03.008_bb0300","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1038\/s41467-023-41145-5","article-title":"MKP1 promotes nonalcoholic steatohepatitis by suppressing AMPK activity through LKB1 nuclear retention","volume":"14","author":"Qiu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.03.008_bb0305","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/s12276-023-01072-3","article-title":"MicroRNA regulation of AMPK in nonalcoholic fatty liver disease","volume":"55","author":"Sun","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.tips.2025.03.008_bb0310","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.1038\/s41467-023-44242-7","article-title":"Cdo1\u2013Camkk2\u2013AMPK axis confers the protective effects of exercise against NAFLD in mice","volume":"14","author":"Chen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.03.008_bb0315","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","article-title":"AMP-activated protein kinase: the current landscape for drug development","volume":"18","author":"Steinberg","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2025.03.008_bb0320","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-022-04431-8","article-title":"Low-dose metformin targets the lysosomal AMPK pathway through PEN2","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.03.008_bb0325","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2025.03.008_bb0330","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2025.03.008_bb0335","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.tips.2023.04.004","article-title":"Striking a gut\u2013liver balance for the antidiabetic effects of metformin","volume":"44","author":"Barroso","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2025.03.008_bb0340","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ads5466","article-title":"Metformin targets mitochondrial complex I to lower blood glucose levels","volume":"10","author":"Reczek","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tips.2025.03.008_bb0345","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122287119","article-title":"Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis","volume":"119","author":"LaMoia","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.03.008_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121706","article-title":"The combination of metformin with morin alleviates hepatic steatosis via modulating hepatic lipid metabolism, hepatic inflammation, brown adipose tissue thermogenesis, and white adipose tissue browning in high-fat diet-fed mice","volume":"323","author":"Tehrani","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.tips.2025.03.008_bb0355","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/metabo14040186","article-title":"Metformin and the liver: unlocking the full therapeutic potential","volume":"14","author":"Perazza","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.tips.2025.03.008_bb0360","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031437","article-title":"Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology","volume":"101","author":"Huang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.tips.2025.03.008_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.649018","article-title":"Efficacy of various hypoglycemic agents in the treatment of patients with nonalcoholic liver disease with or without diabetes: a network meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.tips.2025.03.008_bb0370","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004529","article-title":"Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis","volume":"95","author":"Sawangjit","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.tips.2025.03.008_bb0375","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/2044090","article-title":"Effect and safety of pioglitazone\u2013metformin tablets in the treatment of newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease in shaanxi province: a randomized, double-blinded, double-simulated multicenter study","volume":"2023","author":"Jianfang","year":"2023","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.tips.2025.03.008_bb0380","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2213-8587(14)70050-6","article-title":"Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis","volume":"2","author":"Zhou","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tips.2025.03.008_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.724514","article-title":"AICAR, an AMP-activated protein kinase activator, ameliorates acute pancreatitis-associated liver injury partially through Nrf2-mediated antioxidant effects and inhibition of NLRP3 inflammasome activation","volume":"12","author":"Kong","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2025.03.008_bb0390","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.freeradbiomed.2024.10.259","article-title":"CCCP induces hepatic stellate cell activation and liver fibrogenesis via mitochondrial and lysosomal dysfunction","volume":"225","author":"Lee","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.tips.2025.03.008_bb0395","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1126\/science.1215327","article-title":"The ancient drug salicylate directly activates AMP-activated protein kinase","volume":"336","author":"Hawley","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.03.008_bb0400","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jama.2024.1215","article-title":"Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial","volume":"331","author":"Simon","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2025.03.008_bb0405","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bcpt.13535","article-title":"Salsalate reverses metabolic disorders in a mouse model of non-alcoholic fatty liver disease through AMPK activation and caspase-6 activity inhibition","volume":"128","author":"Li","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.tips.2025.03.008_bb0410","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/hep4.1799","article-title":"Direct AMPK activation corrects NASH in rodents through metabolic effects and direct action on inflammation and fibrogenesis","volume":"6","author":"Gluais-Dagorn","year":"2022","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.tips.2025.03.008_bb0415","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study","volume":"6","author":"Cusi","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2025.03.008_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103910","article-title":"NAFLD and NASH: etiology, targets and emerging therapies","volume":"29","author":"Wei","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2025.03.008_bb0425","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: Insights from clinical trials and error","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tips.2025.03.008_bb0430","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1126\/science.aah5582","article-title":"Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy","volume":"357","author":"Myers","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.03.008_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102042","article-title":"The metabolic sensor AMPK: twelve enzymes in one","volume":"90","author":"Smiles","year":"2024","journal-title":"Mol. Metab."},{"key":"10.1016\/j.tips.2025.03.008_bb0440","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s42255-020-0245-2","article-title":"Long-chain fatty acyl-CoA esters regulate metabolism via allosteric control of AMPK beta1 isoforms","volume":"2","author":"Pinkosky","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.tips.2025.03.008_bb0445","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/a-2438-4383","article-title":"Role of the gut microbiome in metabolic dysfunction-associated steatotic liver disease","volume":"44","author":"Maher","year":"2024","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.tips.2025.03.008_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.717925","article-title":"The role of intestinal permeability in gastrointestinal disorders and current methods of evaluation","volume":"8","author":"Vanuytsel","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.tips.2025.03.008_bb0455","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2337\/db06-1491","article-title":"Metabolic endotoxemia initiates obesity and insulin resistance","volume":"56","author":"Cani","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2025.03.008_bb0460","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/cdd.2017.14","article-title":"AMPK improves gut epithelial differentiation and barrier function via regulating Cdx2 expression","volume":"24","author":"Sun","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.tips.2025.03.008_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101183","article-title":"Deletion of intestinal epithelial AMP-activated protein kinase alters distal colon permeability but not glucose homeostasis","volume":"47","author":"Olivier","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.tips.2025.03.008_bb0470","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3945\/jn.109.104638","article-title":"Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers","volume":"139","author":"Peng","year":"2009","journal-title":"J. Nutr."},{"key":"10.1016\/j.tips.2025.03.008_bb0475","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ebiom.2018.04.009","article-title":"Activation of liver AMPK with PF-06409577 corrects NAFLD and lowers cholesterol in rodent and primate preclinical models","volume":"31","author":"Esquejo","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.tips.2025.03.008_bb0480","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12967-024-05011-2","article-title":"The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review","volume":"22","author":"Nie","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tips.2025.03.008_bb0485","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.3390\/ijms25073746","article-title":"Does resveratrol improve metabolic dysfunction-associated steatotic liver disease (MASLD)?","volume":"25","author":"Kasprzak-Drozd","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:15:45Z","timestamp":1762251345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0165614725000653"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.03.008","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}